Atlas Bio
Switzerland · Biotech · AI
Atlas Bio develops AI models that simulate patient responses to help biopharma teams assess drug development decisions.
Predictive evidence for drug development
Atlas Bio uses human biological data to model how different patient groups may respond to treatments. Its simulations help teams compare mechanisms, choose indications and plan clinical studies before committing to costly development programmes.
The platform produces predicted molecular responses for virtual patient cohorts. Its work supports decisions about which assets to advance or acquire and how to differentiate them from existing treatments.
A Swiss technology and biology team
Simon Romanski and Sebastian Bayer founded Atlas Bio in 2024. The company is based in Basel, Switzerland, and combines AI engineering with scientific and pharmaceutical development expertise.
Funding history
2 rounds · 2 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Seed | $10M | Creandum — Lead | |
| Previously undisclosed pre-seed | $2.5M | First Momentum Ventures — LeadLEA Partners — Lead |